TY - JOUR
T1 - Policies to enhance prescribing efficiency in Europe
T2 - Findings and future implications
AU - Godman, Brian
AU - Shrank, William
AU - Andersen, Morten
AU - Berg, Christian
AU - Bishop, Iain
AU - Burkhardt, Thomas
AU - Garuoliene, Kristina
AU - Herholz, Harald
AU - Joppi, Roberta
AU - Kalaba, Marija
AU - Laius, Ott
AU - Lonsdale, Julie
AU - Malmström, Rickard E.
AU - Martikainen, Jaana E.
AU - Samaluk, Vita
AU - Sermet, Catherine
AU - Schwabe, Ulrich
AU - Teixeira, Inês
AU - Tilson, Lesley
AU - Tulunay, F. Cankat
AU - Vlahović-Palčevski, Vera
AU - Wendykowska, Kamila
AU - Wettermark, Bjorn
AU - Zara, Corinne
AU - Gustafsson, Lars L.
PY - 2011
Y1 - 2011
N2 - Introduction: European countries need to learn from each other to address unsustainable increases in pharmaceutical expenditures. Objective: To assess the influence of the many supply and demand-side initiatives introduced across Europe to enhance prescribing efficiency in ambulatory care. As a result provide future guidance to countries. Methods: Cross national retrospective observational study of utilization (DDDs - defined daily doses) and expenditure (Euros and local currency) of proton pump inhibitors (PPIs) and statins among 19 European countries and regions principally from 2001 to 2007. Demand-side measures categorized under the "4Es" - education engineering, economics, and enforcement. Results: Instigating supply side initiatives to lower the price of generics combined with demand-side measures to enhance their prescribing is important to maximize prescribing efficiency. Just addressing one component will limit potential efficiency gains. The influence of demand-side reforms appears additive, with multiple initiatives typically having a greater influence on increasing prescribing efficiency than single measures apart from potentially "enforcement." There are also appreciable differences in expenditure (xx/1000 inhabitants/ year) between countries. Countries that have not introduced multiple demand side measures to counteract commercial pressures to enhance the prescribing of generics have seen considerably higher expenditures than those that have instigated a range of measures. Conclusions: There are considerable opportunities for European countries to enhance their prescribing efficiency, with countries already learning from each other. The 4E methodology allows European countries to concisely capture the range of current demand-side measures and plan for the future knowing that initiatives can be additive to further enhance their prescribing efficiency.
AB - Introduction: European countries need to learn from each other to address unsustainable increases in pharmaceutical expenditures. Objective: To assess the influence of the many supply and demand-side initiatives introduced across Europe to enhance prescribing efficiency in ambulatory care. As a result provide future guidance to countries. Methods: Cross national retrospective observational study of utilization (DDDs - defined daily doses) and expenditure (Euros and local currency) of proton pump inhibitors (PPIs) and statins among 19 European countries and regions principally from 2001 to 2007. Demand-side measures categorized under the "4Es" - education engineering, economics, and enforcement. Results: Instigating supply side initiatives to lower the price of generics combined with demand-side measures to enhance their prescribing is important to maximize prescribing efficiency. Just addressing one component will limit potential efficiency gains. The influence of demand-side reforms appears additive, with multiple initiatives typically having a greater influence on increasing prescribing efficiency than single measures apart from potentially "enforcement." There are also appreciable differences in expenditure (xx/1000 inhabitants/ year) between countries. Countries that have not introduced multiple demand side measures to counteract commercial pressures to enhance the prescribing of generics have seen considerably higher expenditures than those that have instigated a range of measures. Conclusions: There are considerable opportunities for European countries to enhance their prescribing efficiency, with countries already learning from each other. The 4E methodology allows European countries to concisely capture the range of current demand-side measures and plan for the future knowing that initiatives can be additive to further enhance their prescribing efficiency.
KW - Drugs
KW - Economics
KW - Efficiency
KW - Generics
KW - Pharmaceuticals
KW - Sustainability
UR - http://www.scopus.com/inward/record.url?scp=79952781964&partnerID=8YFLogxK
U2 - 10.3389/fphar.2010.00141
DO - 10.3389/fphar.2010.00141
M3 - Article
AN - SCOPUS:79952781964
SN - 1663-9812
VL - JAN
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - Article 141
ER -